Company News

Solace Eczema Cream To Be Sold as OTC Product in US

Resilia Pharmaceuticals licenses treatment with palmitamide MEA from Pelle Ventures.

Author Image

By: Christine Esposito

Editor-in-Chief

Resilia Pharmaceuticals, Inc. has signed a license agreement with Holland, MI-based Pelle Ventures, LLC that gives Resilia the rights to make, market and sell Solace Eczema Cream as an OTC product in the US. Financial terms of the transaction were not disclosed. Previously only available by prescription, Solace Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin building blocks like cholesterol, fatty acids, and ceramid...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters